Roche’s divarasib reportedly yielded almost six months longer survival than rivals in lung cancer study

Bloomberg reports Roche’s investigational divarasib helped patients whose non-small cell lung cancer had spread live almost six months longer than Amgen’s sotorasib and Bristol-Myers Squibb’s adagrasib in a late-stage study. The Wall Street Journal reports Roche said the drug lowered the risk of death by 44% against available rival treatments. Roche expects the pill to become a new treatment standard, but that remains its expectation.